2. Signaling Pathways
  3. Apoptosis
  4. TNF Receptor
  5. TNFRSF12A/TWEAK Isoform
  6. TNFRSF12A/TWEAK Inhibitor

TNFRSF12A/TWEAK Inhibitor

TNFRSF12A/TWEAK Inhibitors (3):

Cat. No. Product Name Effect Purity
  • HY-P99361
    Enavatuzumab
    		Inhibitor ≥99.0%
    Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
  • HY-P990657
    RG-7212 (RO5458640)
    		Inhibitor 99.62%
    RG-7212 (RO5458640) is a human-derived antibody expressed in CHO cells, targeting TNFSF12/TWEAK. RG-7212 (RO5458640) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.02 kDa. The isotype control for RG-7212 (RO5458640) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-113763
    TWEAK-Fn14-IN-1
    		Inhibitor
    TWEAK-Fn14-IN-1 (Compound L524-0366) is a specific dose-dependent TWEAK-Fn14 inhibitor. TWEAK-Fn14-IN-1 binds specifically to the Fn14 surface with a KD of 7.12 μM. TWEAK-Fn14-IN-1 inhibits TWEAK induced glioma cell migration without any potential cytotoxic effects.